查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594526

非類固醇消炎劑市場：依疾病、藥物、給藥途徑、通路分類 - 全球預測 2025-2030

Non-steroidal Anti-inflammatory Drugs Market by Disease Indication (Arthritis, Migraine, Ophthalmic Diseases), Drugs (Over-the-counter Drugs, Prescription), Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年非類固醇消炎劑市值為217.1億美元，預計2024年將達232.4億美元，複合年成長率為7.53%，預計到2030年將達361億美元。

非類固醇非類固醇消炎劑 非類固醇消炎劑 ）是一類透過抑制Cyclooxygenase來緩解疼痛、減輕發炎、退燒的藥物。這些藥物對於治療關節炎、肌肉疼痛和頭痛等症狀至關重要。非類固醇抗發炎藥的範圍從緩解輕度至中度疼痛的非處方藥到治療慢性發炎疾病的處方藥。最終用途主要包括醫療機構、零售藥局和個人使用者。影響非類固醇抗發炎藥物市場的主要成長要素包括慢性疼痛疾病盛行率的增加、人口老化以及對疼痛管理選擇的認知不斷提高。此外，最大限度地減少消化器官系統道副作用並提高非類固醇抗發炎藥物有效性的配方的進步也帶來了值得注意的市場機會。非類固醇消炎劑配方和聯合治療等創新是業務成長和擴張的潛在途徑。

主要市場統計
基準年[2023] 217.1億美元
預測年份 [2024] 232.4億美元
預測年份 [2030] 361億美元
複合年成長率（%） 7.53%

然而，非類固醇抗發炎藥物具有消化道出血和心血管風險等副作用，這限制了其使用並增加了監管審查，限制了市場成長。此外，替代療法（例如治療發炎疾病的生物製藥）的出現對非類固醇抗發炎藥物構成了競爭。希望利用 NSAID 市場機會的公司可能會受益於專注於開拓更安全的製劑，例如具有改善的胃腸道安全性的製劑或選擇性 COX-2 抑制劑。擴大個人化醫療方法的研究，根據個人的基因特徵客製化非類固醇消炎劑（NSAID）治療，也可以提供競爭優勢。非類固醇消炎劑市場競爭激烈，大型製藥企業在產品差異化和市場滲透策略上投入大量資金。持續監控監管途徑和患者依從模式對於維持成長動能至關重要。參與產品創新的策略夥伴關係和協作研究是有益的。總之，雖然非類固醇消炎劑（NSAID）仍然是疼痛和發炎管理的基石，但解決安全問題和探索新的給藥系統將抓住市場潛力，這是最重要的。

市場動態：揭示快速發展的非類固醇消炎劑市場的關鍵市場洞察

非類固醇消炎劑市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性疼痛病例增加，發炎病例迅速增加
    • 老年人口不斷增加，人們對使用非類固醇消炎劑的認知不斷提高
    • 更多人喜歡非類固醇抗發炎藥而不是鴉片類藥物
  • 市場限制因素
    • 與使用非類固醇消炎劑相關的副作用
  • 市場機會
    • 更快的政府核准和更多的政府措施
    • 新技術、研發活動和新藥上市
  • 市場挑戰
    • 藥物在臨床試驗中失敗

波特五力：駕馭非類固醇消炎劑市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解非類固醇消炎劑市場的外部影響

外部宏觀環境因素在塑造非類固醇消炎劑市場的表現動態中發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解非類固醇消炎劑市場競爭格局

對非類固醇消炎劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣非類固醇消炎劑市場供應商的績效評估

FPNV定位矩陣是評估非類固醇消炎劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，非類固醇消炎劑市場的成功指明道路

對非類固醇消炎劑市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性疼痛病例增加，發炎病例迅速增加
      • 老年人口不斷增加，人們對使用非類固醇消炎劑的認知不斷提高
      • 越來越多的人喜歡非類固醇抗發炎藥而不是鴉片類藥物
    • 抑制因素
      • 與使用非類固醇消炎劑相關的副作用
    • 機會
      • 政府快速核准和政府主導措施增多
      • 新興技術、研發活動及新藥上市
    • 任務
      • 藥物在臨床試驗中失敗
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章非類固醇消炎劑市場：依疾病適應症

  • 關節炎
  • 偏頭痛
  • 眼科疾病

第7章非類固醇消炎劑市場（依藥品）

  • 非處方藥
    • 阿斯匹靈（Bufferin、拜耳、Excedrin）
    • Ibuprofen（Advil、Motrin、Nuprin）
    • 酮洛芬（Actron，Ordis）
    • 萘普生（Aleve）
  • 處方箋
    • 日親
    • 印度支那
    • 羅丹
    • 萘普生
    • 利拉芬
    • 維莫沃
    • Voltaren

第8章非類固醇消炎劑市場：依給藥途徑

  • 口服
  • 胃腸外的

第9章非類固醇消炎劑市場：依分銷管道分類

  • 藥局
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章美洲非類固醇消炎劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太非類固醇消炎劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲非類固醇消炎劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Apotex Inc.
  • Assertio Therapeutics, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Iroko Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Perrigo Company PLC
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-7C50F2739687

The Non-steroidal Anti-inflammatory Drugs Market was valued at USD 21.71 billion in 2023, expected to reach USD 23.24 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 36.10 billion by 2030.

Non-steroidal Anti-inflammatory Drugs (NSAIDs) are a class of medications used to alleviate pain, decrease inflammation, and reduce fever by inhibiting cyclooxygenase enzymes. These drugs are essential in managing conditions like arthritis, muscular pain, and headaches. The application scope of NSAIDs spans over-the-counter use for mild to moderate pain relief and prescription use for chronic inflammatory diseases. The end-use scope primarily includes healthcare facilities, retail pharmacies, and individual users. Key growth factors influencing the NSAID market include increasing prevalence of chronic pain conditions, an aging population, and heightened awareness of pain management options. Moreover, advancements in drug formulations that minimize gastrointestinal side effects and elevate the efficacy of NSAIDs present noteworthy market opportunities. Innovations like topical NSAID forms and combination therapies serve as potential avenues for business growth and expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 21.71 billion
Estimated Year [2024] USD 23.24 billion
Forecast Year [2030] USD 36.10 billion
CAGR (%) 7.53%

However, market growth faces limitations, notably due to the side effects of NSAIDs, such as gastrointestinal bleeding and cardiovascular risks, which can deter usage and lead to stringent regulatory scrutiny. Additionally, the advent of alternative therapies like biologics for inflammatory conditions poses competition to NSAIDs. For companies aiming to capitalize on NSAID market opportunities, focusing on developing safer formulations, such as those with improved gastrointestinal safety profiles or selective COX-2 inhibitors, can be advantageous. Expanding research into personalized medicine approaches that tailor NSAID therapies to individual genetic profiles can also offer a competitive edge. The nature of the NSAID market is highly competitive, with major pharmaceutical companies investing heavily in product differentiation and market penetration strategies. Continued surveillance of regulatory pathways and patient compliance patterns is crucial for maintaining growth momentum. Engaging in strategic partnerships and collaborations for product innovation can be instrumental. In conclusion, while NSAIDs remain a cornerstone in pain and inflammation management, addressing safety concerns and exploring novel drug-delivery systems will be paramount in harnessing market potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-steroidal Anti-inflammatory Drugs Market

The Non-steroidal Anti-inflammatory Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in chronic pain cases and surge in inflammation cases
    • Increasing geriatric population and rising awareness about the use of non-steroidal anti-inflammatory drugs
    • Increasing preference of people for nsaids over opioids
  • Market Restraints
    • Side effects associated with the use of non-steroidal anti-inflammatory drugs
  • Market Opportunities
    • Quick authority approvals by the governments and increase in government initiatives
    • Emerging technology, research and development activities, and launch of novel drugs
  • Market Challenges
    • Failure of drug during the clinical trial

Porter's Five Forces: A Strategic Tool for Navigating the Non-steroidal Anti-inflammatory Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-steroidal Anti-inflammatory Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-steroidal Anti-inflammatory Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-steroidal Anti-inflammatory Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-steroidal Anti-inflammatory Drugs Market

A detailed market share analysis in the Non-steroidal Anti-inflammatory Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-steroidal Anti-inflammatory Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-steroidal Anti-inflammatory Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-steroidal Anti-inflammatory Drugs Market

A strategic analysis of the Non-steroidal Anti-inflammatory Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-steroidal Anti-inflammatory Drugs Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Assertio Therapeutics, Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline PLC, Iroko Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Perrigo Company PLC, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Non-steroidal Anti-inflammatory Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Indication, market is studied across Arthritis, Migraine, and Ophthalmic Diseases.
  • Based on Drugs, market is studied across Over-the-counter Drugs and Prescription. The Over-the-counter Drugs is further studied across Aspirin (Bufferin, Bayer, & Excedrin), Ibuprofen (Advil, Motrin, Nuprin), Ketoprofen (Actron, Orudis), and Naproxen (Aleve). The Prescription is further studied across Daypro, Indocin, Lodine, Naprosyn, Relafen, Vimovo, and Voltaren.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in chronic pain cases and surge in inflammation cases
      • 5.1.1.2. Increasing geriatric population and rising awareness about the use of non-steroidal anti-inflammatory drugs
      • 5.1.1.3. Increasing preference of people for nsaids over opioids
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with the use of non-steroidal anti-inflammatory drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Quick authority approvals by the governments and increase in government initiatives
      • 5.1.3.2. Emerging technology, research and development activities, and launch of novel drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Failure of drug during the clinical trial
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Non-steroidal Anti-inflammatory Drugs Market, by Disease Indication

  • 6.1. Introduction
  • 6.2. Arthritis
  • 6.3. Migraine
  • 6.4. Ophthalmic Diseases

7. Non-steroidal Anti-inflammatory Drugs Market, by Drugs

  • 7.1. Introduction
  • 7.2. Over-the-counter Drugs
    • 7.2.1. Aspirin (Bufferin, Bayer, & Excedrin)
    • 7.2.2. Ibuprofen (Advil, Motrin, Nuprin)
    • 7.2.3. Ketoprofen (Actron, Orudis)
    • 7.2.4. Naproxen (Aleve)
  • 7.3. Prescription
    • 7.3.1. Daypro
    • 7.3.2. Indocin
    • 7.3.3. Lodine
    • 7.3.4. Naprosyn
    • 7.3.5. Relafen
    • 7.3.6. Vimovo
    • 7.3.7. Voltaren

8. Non-steroidal Anti-inflammatory Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Drug Store
  • 9.3. Hospital Pharmacy
  • 9.4. Online Pharmacy
  • 9.5. Retail Pharmacy

10. Americas Non-steroidal Anti-inflammatory Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Non-steroidal Anti-inflammatory Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Non-steroidal Anti-inflammatory Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Assertio Therapeutics, Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Boehringer Ingelheim International GmbH
  • 6. Eli Lilly and Company
  • 7. GlaxoSmithKline PLC
  • 8. Iroko Pharmaceuticals Inc.
  • 9. Johnson & Johnson Services, Inc.
  • 10. Merck & Co., Inc.
  • 11. Perrigo Company PLC
  • 12. Pfizer Inc.
  • 13. Reckitt Benckiser Group PLC
  • 14. Sanofi S.A.
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN (BUFFERIN, BAYER, & EXCEDRIN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN (ADVIL, MOTRIN, NUPRIN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN (ACTRON, ORUDIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN (ALEVE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DAYPRO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDOCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY LODINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROSYN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELAFEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY VIMOVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY VOLTAREN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRU